Phase I of XKH002 Injection in Patients
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- Drug: XKH002 Injection
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
- Target Recruit Count
- 110
- Registration Number
- NCT06196762
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, China
© Copyright 2025. All Rights Reserved by MedPath